⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL135549 | 1.00 | — | — | |
| SCHEMBL9773255 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL28814183 | 0.97 | — | — | |
| Benzene SCHEMBL28580663 | 0.95 | NR4A2 (0.38) | — | |
| Sulfuric Acid SCHEMBL28623602 | 0.87 | ALDH1A1 (0.38) | — | |
| SCHEMBL25397821 | 0.75 | MAP4K4 (0.46) | — | |
| SCHEMBL5955760 | 0.73 | — | — | |
| SCHEMBL30240827 | 0.73 | — | — | |
| SCHEMBL4614 | 0.72 | — | — | |
| SCHEMBL22912663 | 0.72 | IDO1 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090477-A1 | HELICASE INHIBITORS AND USES THEREOF | KIMIA THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4705291-A1 | IKK-ALPHA INHIBITORS | Cancer Research Technology Limited (GB) | 2026-03-11 | — | — | EP | disclosed |
| US-20260008767-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | CRINETICS PHARMACEUTICALS INC (US) | 2026-01-08 | — | — | US | disclosed |
| WO-2025038927-A1 | MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF | RAYTHERA, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| WO-2024228035-A1 | IKK-ALPHA INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-11-07 | — | — | WO | disclosed |
| EP-4408849-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | Caraway Therapeutics, Inc. (US) | 2024-08-07 | — | — | EP | disclosed |
| EP-4408850-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | Caraway Therapeutics, Inc. (US) | 2024-08-07 | — | — | EP | disclosed |
| EP-4347032-A1 | SUBSTITUTED TETRAHYDROFURAN-2-CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4178620-A1 | PLASMA KALLIKREIN INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-05-17 | — | — | EP | disclosed |
| EP-4163276-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| WO-2023055920-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| WO-2023055912-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| WO-2022256702-A1 | SUBSTITUTED TETRAHYDROFURAN-2-CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-12-08 | — | — | WO | disclosed |
| US-20220380337-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2022-12-01 | — | — | US | disclosed |
| EP-4055019-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | Nurix Therapeutics, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| EP-3484865-B1 | SOMATOSTATIN MODULATORS AND USES THEREOF | CRINETICS PHARMACEUTICALS INC (US) | 2022-09-14 | — | — | EP | disclosed |
| EP-4055016-A1 | GPR52 MODULATOR COMPOUNDS | Heptares Therapeutics Limited (GB) | 2022-09-14 | — | — | EP | disclosed |
| US-11414397-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2022-08-16 | — | — | US | disclosed |